DYNASTY-Breast02 met its primary endpoint, but immature overall survival data and lung-safety findings lead partners to reassess the therapy's potential benefit BioNTech and DualityBio announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results